Views: 1,308 | Downloads:
25
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Methyldopa Supplement for Resistant Essential Hypertension : A Prospective Randomized Placebo Control Crossover Study
Sermswan A 
,
N
,
N Background : Resistant hypertension is an important public health problem, its prevalence
varies between 30 to 50 per cent. However, there is no definite recommendation for the treatment of
resistant hypertension (HT).
Material and Method: A prospective randomized placebo control crossover study in resistant
HT was designed to compare safety and efficacy between methyldopa 250 mg twice daily and placebo
using ambulatory blood pressure monitoring.
Results: 87 from 1,112 cases (7.82%) from the hypertension clinic of Vajira Hospital were
found to have clinical resistant HT and 40 cases were accepted to enrolled in the study. 23 cases of
true resistant HT proceeded to the treatment phase of the study and all of them completed the study.
Methyldopa reduced systolic blood pressure (BP) from 153.67 to 135.23 mmHg, or -18.44 mmHg (95%
confidence interval 15.13-21.75). Diastolic BP was reduced from 86.42 to 74.90 mmHg, or -11.52
mmHg (95% confidence interval9.41-13.63).
Conclusion :The addition of methyldopa to the optimal medical therapy contributed to the
improvement of BP control among patients with resistant HT.
Key word : Resistant Hypertension, Methyldopa, Ambulatory Blood Pressure Monitoring
varies between 30 to 50 per cent. However, there is no definite recommendation for the treatment of
resistant hypertension (HT).
Material and Method: A prospective randomized placebo control crossover study in resistant
HT was designed to compare safety and efficacy between methyldopa 250 mg twice daily and placebo
using ambulatory blood pressure monitoring.
Results: 87 from 1,112 cases (7.82%) from the hypertension clinic of Vajira Hospital were
found to have clinical resistant HT and 40 cases were accepted to enrolled in the study. 23 cases of
true resistant HT proceeded to the treatment phase of the study and all of them completed the study.
Methyldopa reduced systolic blood pressure (BP) from 153.67 to 135.23 mmHg, or -18.44 mmHg (95%
confidence interval 15.13-21.75). Diastolic BP was reduced from 86.42 to 74.90 mmHg, or -11.52
mmHg (95% confidence interval9.41-13.63).
Conclusion :The addition of methyldopa to the optimal medical therapy contributed to the
improvement of BP control among patients with resistant HT.
Key word : Resistant Hypertension, Methyldopa, Ambulatory Blood Pressure Monitoring
Download:
PDF